Serum prolidase enzyme activity and oxidative status in patients with fibromyalgia

Basit Öğe Kaydı
dc.contributor.authorBozkurt, Mehtap
dc.contributor.authorCaglayan, Mehmet
dc.contributor.authorOktayoglu, Pelin
dc.contributor.authorEm, Serda
dc.contributor.authorBatmaz, Ibrahim
dc.contributor.authorSariyildiz, Mustafa Akif
dc.contributor.authorNas, Kemal
dc.date.accessioned2024-04-24T17:14:47Z
dc.date.available2024-04-24T17:14:47Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: This study was performed to investigate serum prolidase enzyme activity and oxidative stress in patients diagnosed with fibromyalgia (FM). Methods: The study population consisted of 40 patients with a previous diagnosis of FM and 30 healthy subjects. We measured serum prolidase enzyme activity, total antioxidant status (TAS), total oxidative status (TOS), oxidative stress index (OSI), and paraoxonase-1 (PON-1) levels. Results: On average, FM patients were diagnosed within 3.2 years of symptom onset, and patients had a mean of 14 tender points. There were no significant differences between patients and controls in age, body mass index, serum TAS, or PON-1 levels. However, patients with FM demonstrated higher serum prolidase activity, TOS, and OSI than the control group. Serum prolidase activity was positively correlated with serum TOS, OSI, and visual analog scale pain and fatigue scores. No correlation was found between serum prolidase activity and FM duration or the average number of tender points. Discussion: Our results demonstrate a previously unreported association between serum prolidase enzyme activity and FM. Increased prolidase activity may contribute to the pathogenesis of FM, and measuring serum prolidase enzyme activity may be a useful FM biomarker.en_US
dc.identifier.doi10.1179/1351000213Y.0000000079
dc.identifier.endpage153en_US
dc.identifier.issn1351-0002
dc.identifier.issn1743-2928
dc.identifier.issue4en_US
dc.identifier.pmid24620938
dc.identifier.scopus2-s2.0-84901315974
dc.identifier.scopusqualityQ2
dc.identifier.startpage148en_US
dc.identifier.urihttps://doi.org/10.1179/1351000213Y.0000000079
dc.identifier.urihttps://hdl.handle.net/11468/18189
dc.identifier.volume19en_US
dc.identifier.wosWOS:000337130500002
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofRedox Report
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectProlidaseen_US
dc.subjectOxidative Statusen_US
dc.subjectFibromyalgiaen_US
dc.titleSerum prolidase enzyme activity and oxidative status in patients with fibromyalgiaen_US
dc.titleSerum prolidase enzyme activity and oxidative status in patients with fibromyalgia
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu